The mRNA-1345 RSV Vaccine Conundrum: A Deeper Dive into the Rabbit Hole ๐Ÿšจ๐Ÿงฌ๐Ÿ’‰

by DickVegas on June 4, 2024 at 6:20 am
Posted In: BioWars, Turning People into Patients ๐Ÿงฌโš”๏ธ๐Ÿฅ, DV13 Chronicles ๐Ÿ“š๐Ÿ•ต๏ธโ€โ™‚๏ธโœจ, Nanotechnology, Nanobots, Nanodust ๐Ÿค–๐Ÿ”ฌ๐ŸŒŒ, The Threat of Big PHARM-A ๐Ÿ’Šโš ๏ธ๐Ÿ’‰, Vaccine Dangers and Risks ๐Ÿ’‰โš ๏ธ๐Ÿšซ, โœจ New Series: DV-13 Chronicles Unveiled! โœจ
The Pandemic Piggy Bank: Government Spending Gone Wild! ๐Ÿค‘๐Ÿ’‰

The mRNA-1345 Conundrum: A Deeper Dive into the Rabbit Hole

Ladies and gentlemen, gather โ€˜round, for we are about to embark on a journey into the twisted, mind-bending labyrinth of the modern medical-industrial complex. Today, we peel back the layers on Moderna’s latest concoction: the mRNA-1345 RSV vaccine, recently rubber-stamped by the FDA. But oh, donโ€™t be fooled by the sanitized headlines and glowing reports! ๐Ÿšจ๐Ÿงฌ๐Ÿ’‰

The trials, they say, were a roaring success. But letโ€™s dig deeper, shall we? This vaccine, targeting the respiratory syncytial virus (RSV), is being pushed on our elders, the ones who rely on their golden years to be tranquil, not filled with experimental injections. The official narrative sings praises of โ€œefficacyโ€ and โ€œprotection,โ€ but what they bury deep within their documents are the adverse effects. Yes, dear readers, adverse effects that could send chills down your spine!

In the clinical trials for adults aged 60 and above, many participants reported typical vaccine side effectsโ€”pain, redness, swelling at the injection site, fatigue, and fever. These might seem benign, but wait until you hear about the serious adverse events (SAEs). A small percentage of participants experienced these SAEs, but the connection to the vaccine remains a shadowy figure in the background, conveniently obscured by corporate jargon and statistical smoke scre [โž] [โž]ceใ€‘.

For our precious children, the story doesnโ€™t get any brighter. Trials for kids aged 2 to 17 years old reported adverse reactions such as headaches, fatigue, and fever. Some required medical attention, a harrowing thought for any parent. Yet, weโ€™re assured everything is โ€œwithin expected ranges.โ€ Expected by whom? Certainly not by the parents who trusted these institutions with their childrenโ€™s saf [โž]ceใ€‘.

And donโ€™t even get me started on the trials involving pregnant women and their newborns. Imagine the audacity of injecting expecting mothers with an experimental vaccine and then watching their infants for any fallout! Itโ€™s almost as if weโ€™re living in a dystopian novel where human beings are mere lab rats in a grand experiment orchestrated by Big Pha [โž]ceใ€‘.

Oh, and letโ€™s not forget the seniors who received this RSV vaccine alongside their flu shots. Co-administration, they call it. What could possibly go wrong? According to the data, plenty! Participants reported a slew of adverse reactions, with some experiencing severe systemic responses. But of course, these reactions are downplayed in favor of pushing the vaccine agenda forw [โž]ceใ€‘.

So, my fellow truth-seekers, stay vigilant, stay informed, and never take the spoon-fed narratives at face value. The web of deception is vast and complex, and itโ€™s our duty to unravel it, one thread at a time.

Written by Dick Vegas, approved by Kenny Valenzuela, experimentalvaccines.org.

The Silent Killers: The Unseen Hand of the COVID Cover-Up ๐Ÿ’€๐Ÿ“ˆ

The clinical trials for Moderna’s mRNA-1345 RSV vaccine have reported a range of adverse effects, which are summarized below based on the different studies:

  1. Study in Adults Aged 60 and Older:
  • Local and Systemic Adverse Reactions: Participants experienced typical vaccine-related reactions such as pain at the injection site, redness, swelling, fatigue, headache, muscle pain, and fever. These were generally mild to moderate in severity and resolved within a few days.
  • Serious Adverse Events (SAEs): A small percentage of participants reported serious adverse events, but these were not necessarily linked to the vaccine. The study monitored for any significant health changes, but no widespread severe reactions were attributed directly to the vaccine [โž] [โž].
  1. Study in Children Aged 2 to 17 Years:
  • Adverse Reactions: Common side effects included injection site pain, fatigue, headache, and fever. These reactions were consistent with those observed in other age groups and were typically short-lived.
  • Medically Attended Adverse Events (MAAEs): Some children experienced adverse events requiring medical attention, but these were within expected ranges for vaccine studies and not specifically attributed to the vaccine itself [โž].
  1. Study in Pregnant Women and Infants:
  • Maternal and Infant Adverse Events: Pregnant women reported typical vaccine reactions such as pain at the injection site, fever, and fatigue. Infants born to vaccinated mothers were monitored for any adverse effects, and while some adverse events were reported, they were not significantly higher than those in the control group.
  • Serious Adverse Events: Serious adverse events in both mothers and infants were tracked, with no significant increase in severe reactions directly linked to the vaccine [โž].
  1. Co-administration with Influenza Vaccine in Adults 65 and Older:
  • Adverse Reactions: Participants receiving both the RSV and influenza vaccines reported local and systemic reactions similar to those seen with each vaccine alone. The most common were injection site pain, fatigue, and headache.
  • Serious Adverse Events: The study monitored for serious adverse events, finding no significant increase compared to the control groups receiving either vaccine alone [โž].

Overall, while common vaccine-related side effects were reported in these studies, including pain at the injection site, fatigue, headache, and fever, serious adverse events were rare and not conclusively linked to the mRNA-1345 vaccine. The findings suggest that the vaccine has a safety profile comparable to other vaccines in use. For more detailed information, refer to the individual trial results on ClinicalTrials.gov.

Here is a detailed overview of the clinical trials for Moderna’s mRNA-1345 RSV vaccine:

  1. Study in Adults Aged 60 and Older: This trial evaluated the safety and efficacy of mRNA-1345 in preventing RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 and older. The study measured the vaccine’s efficacy in preventing RSV-LRTD and acute respiratory disease (RSV-ARD) by monitoring participants for confirmed RSV infections and hospitalizations over 12 months post-injection [โž].
  2. Study in Children Aged 2 to 17 Years: This trial assessed the safety, reactogenicity, and immunogenicity of mRNA-1345 in children at high risk of RSV. Participants received either the vaccine or a placebo, and the study measured local and systemic adverse reactions, as well as immunogenicity through neutralizing antibody titers over six months [โž].
  3. Study in Pregnant Women and Infants: This trial focused on the safety and immunogenicity of mRNA-1345 in pregnant women and the subsequent protection in their infants. The primary outcomes included maternal and infant adverse events, antibody responses, and pregnancy outcomes such as birth methods and gestational age [โž].
  4. Co-administration with Influenza Vaccine in Adults 65 and Older: This trial investigated the safety and immune response when mRNA-1345 is co-administered with a high-dose influenza vaccine (Fluzone HD) in adults aged 65 and older. The study measured adverse reactions, antibody responses to both vaccines, and the overall safety profile over several months [โž].
  5. Study in Adults Aged 50 and Older: This trial evaluated the safety, tolerability, and immunogenicity of mRNA-1345, both alone and in combination with another mRNA vaccine. It included multiple cohorts receiving different vaccine combinations, and measured adverse reactions, antibody titers, and overall safety over a year [โž].

For more detailed information, you can visit the specific trial pages on ClinicalTrials.gov.

Pfizerโ€™s Argentine Nightmare: Criminal Charges Unleashed! ๐Ÿ’‰๐Ÿ’ฅ

Here are six articles discussing Moderna’s mRNA-1345 RSV vaccine:

  1. Moderna Announces Update on Investigational RSV Vaccine
    This article provides an update on Moderna’s ongoing review process with the FDA for their mRNA-1345 RSV vaccine. Due to administrative constraints, the FDA has delayed its decision, but Moderna remains optimistic about the vaccine’s approval and upcoming review at the CDC’s ACIP meeting [โž].
  2. Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
    This article announces the FDA approval of Moderna’s mRNA-1345 RSV vaccine, branded as mRESVIA, for adults aged 60 and older. The vaccine demonstrated significant efficacy and safety in clinical trials, marking an important milestone for mRNA technology beyond COVID-19 vaccines [โž].
  3. Modernaโ€™s RSV Vaccine Demonstrates Safety and Efficacy for 8 Months
    This piece details the long-term safety and efficacy data of the mRNA-1345 RSV vaccine, showing continued protection against RSV lower respiratory tract disease in older adults over an 8-month period. The vaccine was well-tolerated with no major safety concerns [โž].
  4. mRNA Vaccine Effective Against RSV Respiratory Disease
    Published in Nature Medicine, this article discusses the clinical trial results of the mRNA-1345 vaccine, highlighting its efficacy in preventing RSV-related illnesses in older adults. The vaccine uses the same mRNA technology as Moderna’s COVID-19 vaccines and has shown promising results [โž].
  5. Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine
    This article covers the FDA’s approval of Moderna’s mRNA-1345 as a single-dose RSV vaccine for adults over 60. It emphasizes the vaccine’s efficacy and its design to simplify administration and reduce errors [โž].
  6. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
    Published in the New England Journal of Medicine, this article reports on the phase 3 trial of the mRNA-1345 RSV vaccine, showing high efficacy and a favorable safety profile in preventing lower respiratory tract disease in older adults [โž].

These articles provide comprehensive coverage of the mRNA-1345 RSV vaccine, from clinical trials to regulatory approvals, highlighting both its potential benefits and the rigorous testing it has undergone.